Solid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat forecasts, and could spell trouble for rival Eli Lilly this year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,